Heat Biologics Inc. (NASDAQ: HTBX) was established in 2008 and is headquartered in Durham, North Carolina, USA. It has 19 full-time employees. It is a clinical-stage biopharmaceutical company that focuses on the development and development of a series of cancer and infectious disease vaccines. Commercial application.
Heat Biologics (HTBX):
Heat Biologics focuses on developing methods to activate and co-stimulate the patient’s anti-cancer immune system. The company’s T-cell activation platform (TCAP) produces therapies designed to warm immune-cold tumors and combine them with checkpoint inhibitors and other Immunomodulators are used in combination to improve clinical effects.
Heat Biologics TCAP product candidates include ImPACT platform technology, which can develop candidate products, including live, heterologous ready-made genetically modified and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy (combination pan-antigen Cytotoxic Therapy ), dual-action immunotherapy, designed to provide T cell activation and enhancement and T cell-specific costimulation in a single treatment.
Products being developed by Heat Biologics include:
HS-110, combined with Bristol-Myers Squibb ‘s nivolumab (Opdivo) for the treatment of non-small cell lung cancer, is currently in phase II clinical stage.
Heat Biologics’ preclinical products include:
HS-130, used to treat non-muscle invasive bladder cancer; and PTX-35 and PTX-15, used to treat tumors and hematological malignancies.